Mirxes wins China’s approval to launch groundbreaking blood test for gastric cancer
The non-invasive blood test helps in the early detection of the fifth leading cause of cancer deaths globally
Cancer screening device developer Mirxes Holding has won approval from Beijing to launch a gastric cancer test, the first blood test for the disease in China’s vast oncology diagnostics market.
“GastroClear is the world’s first microRNA blood test approved for the early detection of gastric cancer, evaluating gastric cancer risk by detecting 12 gastric cancer-associated miRNA biomarkers,” it said.
“The company will continue to expand its investment in scaling commercialisation in China, including increasing the size of its sales team and enhancing local production capacity.”
Gastric cancer was the fifth leading cause of cancer deaths in 2023 globally, and ranked fifth in terms of global incidences that totalled around 1 million among all new cancer cases reported that year, according to Frost & Sullivan.